Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.10T
Market cap1.10T
Price-Earnings ratio
40.16
Price-Earnings ratio40.16
Dividend yield
0.57%
Dividend yield0.57%
Average volume
2.33M
Average volume2.33M
High today
$1,190.00
High today$1,190.00
Low today
$1,165.63
Low today$1,165.63
Open price
$1,184.54
Open price$1,184.54
Volume
342.63K
Volume342.63K
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$712.05
52 Week low$712.05

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,167.84, giving the company a market capitalization of 1.1T. It carries a P/E multiple of 40.16 and pays a dividend yield of 0.57%.

On 2026-09-25, Eli Lilly(LLY) stock traded between a low of $1,165.63 and a high of $1,190.00. Shares are currently priced at $1,167.84, which is +0.2% above the low and -1.9% below the high.

The Eli Lilly(LLY)'s current trading volume is 342.63K, compared to an average daily volume of 2.33M.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

LLY News

TipRanks 3h
Nektar Wins $90 Million Verdict in Lilly Dispute

Nektar Therapeutics ( (NKTR) ) has issued an announcement. In August 2023, Nektar Therapeutics filed a complaint in the U.S. District Court for the Northern Di...

CNBC 3h
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

Key Points Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to...

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Simply Wall St 4h
Eli Lilly Shares Just Moved, So What Is Driving Attention Now?

Eli Lilly (LLY) just secured U.S. FDA approval for Onswik, a once weekly basal insulin for adults with type 2 diabetes, an update that quickly drew investor att...

Eli Lilly Shares Just Moved, So What Is Driving Attention Now?

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

The Motley Fool 18h
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?

Choosing between AbbVie (ABBV +0.01%) and Eli Lilly and Co (LLY +2.69%) requires weighing established income against explosive growth. Both companies lead the p...

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
CNBC 19h
Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly - CNBC

...

Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly - CNBC
TipRanks 22h
Lilly’s AI Retinal Scan Study Adds a New Angle to Alzheimer’s Investing

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly and Company is running a new observational study in the U.A.E. that...

Benzinga 22h
Lilly Wins FDA Nod For Weekly Insulin, Signs $3.25 Billion InnoCare Pact

On Thursday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Co.’s (NYSE:LLY) Onswik (insulin efsitora alfa-gobe), a once-weekly basal insuli...

Lilly Wins FDA Nod For Weekly Insulin, Signs $3.25 Billion InnoCare Pact
TipRanks 22h
Eli Lilly Stock Jumps 4% After FDA Approves Diabetes Insulin

The stock of Eli Lilly (LLY) is up 4% after the U.S. Food and Drug Administration (FDA) approved “Onswik,” a once-weekly insulin that treats adults with Type 2...

TipRanks 1d
Eli Lilly announces FDA approval of Onswik for type 2 diabetes

Eli Lilly (LLY) and Company announced the U.S. Food and Drug Administration approval of Onswik, a once-weekly basal insulin, indicated along with diet and exerc...

Simply Wall St 1d
Eli Lilly Targets Up To Five New Medicines In Research Deal

Eli Lilly (NYSE: LLY) agreed a research collaboration and licensing deal with InnoCare Pharma to pursue up to five new medicines. The partners plan to target s...

Eli Lilly Targets Up To Five New Medicines In Research Deal

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.